Compare Charles River Laboratories Intl. Inc (CRL) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.77 (market cap $17.53B). The key difference: iShares Broad USD Investment Grade Corporate Bond is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| CRL | USIG | |
|---|---|---|
Market Cap | $14.23B | $17.53B |
Volume | 1,176,885 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $310.77 | $52.69 |
52-Week Low | $149.93 | $48.54 |
Typical Hold Time | 33 Days | 44 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
USIG trades at $48.765 with minimal daily movement (+0.17%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The stock faces resistance at $49 levels while finding support at $48. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon's increased stake, indicating institutional confidence.
The bearish technical setup contrasts with institutional accumulation, creating a divergence worth monitoring. Key risks include market volatility and competitive pressures in the investment grade corporate bond ETF space. The absence of current fundamental metrics requires careful due diligence on underlying bond portfolio quality and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
